GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyoKardia Inc (NAS:MYOK) » Definitions » EBIT

MyoKardia (MyoKardia) EBIT : $-283.18 Mil (TTM As of Sep. 2020)


View and export this data going back to 2015. Start your Free Trial

What is MyoKardia EBIT?

MyoKardia's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2020 was $-85.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2020 was $-283.18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MyoKardia's annualized ROC % for the quarter that ended in Sep. 2020 was -376.58%. MyoKardia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -472.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MyoKardia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was -2.54%.


MyoKardia EBIT Historical Data

The historical data trend for MyoKardia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyoKardia EBIT Chart

MyoKardia Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EBIT
Get a 7-Day Free Trial -22.90 -10.53 -58.67 -73.65 -207.83

MyoKardia Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.12 -61.41 -71.78 -64.59 -85.40

Competitive Comparison of MyoKardia's EBIT

For the Biotechnology subindustry, MyoKardia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MyoKardia's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MyoKardia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MyoKardia's EV-to-EBIT falls into.



MyoKardia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-283.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyoKardia  (NAS:MYOK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MyoKardia's annualized ROC % for the quarter that ended in Sep. 2020 is calculated as:

ROC % (Q: Sep. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2020 ) + Invested Capital (Q: Sep. 2020 ))/ count )
=-341.612 * ( 1 - -0.01% )/( (81.64 + 99.808)/ 2 )
=-341.6461612/90.724
=-376.58 %

where

Invested Capital(Q: Sep. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1035.661 - 44.597 - ( 895.879 - max(0, 52.488 - 943.744+895.879))
=99.808

Note: The Operating Income data used here is four times the quarterly (Sep. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

MyoKardia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2020  Q: Sep. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-341.612/( ( (70.892 + max(-28.874, 0)) + (70.415 + max(3.268, 0)) )/ 2 )
=-341.612/( ( 70.892 + 73.683 )/ 2 )
=-341.612/72.2875
=-472.57 %

where Working Capital is:

Working Capital(Q: Jun. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 7.075) - (35.949 + 0 + 0)
=-28.874

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 47.865) - (44.597 + 0 + 0)
=3.268

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MyoKardia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2020 )
=-283.179/11148.579
=-2.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyoKardia EBIT Related Terms

Thank you for viewing the detailed overview of MyoKardia's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


MyoKardia (MyoKardia) Business Description

Traded in Other Exchanges
N/A
Address
1000 Sierra Point Parkway, Brisbane, CA, USA, 94005
MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It uses its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. The company's products include MYK-461 s an orally administered small molecule to reduce excessive cardiac muscle contractility leading to HCM.
Executives
Anastasios Gianakakos director, officer: President and CEO 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Denelle J Waynick officer: General Counsel C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary B Cranston director C/O VISA INC., P.O. BOX 8999, SAN FRANCISCO CA 94128-8999
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
David P Meeker director C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
Wendy L Yarno director
Sunil Agarwal director 60 LEVERONI COURT, NOVATO CA 94949
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jake Bauer officer: Chief Business Officer C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Taylor C. Harris officer: Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
William Fairey officer: See Remarks C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Cynthia J Ladd officer: General Counsel C/O AGY THERAPEUTICS INC, 290 UTAH AVE, SOUTH SAN FRANCISCO CA 94080
Robert Scott Mcdowell officer: Chief Scientific Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
June Lee officer: EVP, Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017